Skip to main content

Advertisement

Table 1 Antimicrobial susceptibility of 228 Neisseria gonorrhoeae isolates from Poland in 2010-2012

From: Antimicrobial susceptibility/resistance and genetic characteristics of Neisseria gonorrhoeaeisolates from Poland, 2010-2012

Antimicrobial (Breakpoints (mg/L)) Susceptible no. (%) Intermediate susceptible no. (%) Resistant no. (%)
2010 2011 2012 2010 2011 2012 2010 2011 2012
Ceftriaxone (S ≤ 0.125, I = NA, R > 0.125)* 28 (100) 92 (100) 108 (100) NA NA NA 0 0 0
Cefixime (S ≤ 0.125, I = NA, R > 0.125)* 28 (100) 92 (100) 108 (100) NA NA NA 0 0 0
Spectinomycin (S ≤ 64, I = NA, R > 64)* 28 (100) 92 (100) 108 (100) NA NA NA 0 0 0
Azithromycin (S ≤ 0.25, I = 0.5, R > 0.5)* 23 (82.1) 60 (65.2) 63 (58.3) 2 (7.1) 26 (28.3) 34 (31.5) 3 (10.7) 6 (6.5) 11 (10.2)
Penicillin G (S ≤ 0.064, I = 0.125-1.0, R > 1.0)* 3 (10.7) 7 (7.6) 3 (2.8) 17 (60.7) 72 (78.3) 75 (69.4) 8 (28.6) 13 (14.1) 30 (27.8)
Tetracycline (S ≤ 0.5, I = 1.0, R > 1.0)* 12 (42.9) 31 (33.7) 26 (24.1) 4 (14.3) 26 (28.3) 31 (28.7) 12 (42.9) 35 (38.0) 51 (47.2)
Ciprofloxacin (S ≤ 0.032, I = 0.064, R > 0.064)* 10 (35.7) 46 (50) 34 (31.5) 0 0 0 18 (64.3) 46 (50) 74 (68.5)
Gentamicin** MIC range: 0.032-8 mg/L; MIC50: 4 mg/L; and MIC90: 4 mg/L  
β-lactamase production 2010: 6 (21.4%) ; 2011: 2 (2.2%); and 2012: 4 (3.7%)  
  1. NA, not applicable.
  2. *Breakpoints for susceptible (S  x mg/L) and resistant (R > y mg/L) according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST; http://www.eucast.org).
  3. **Breakpoints not stated by any organization.